Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib vs Chemotherapy in EGFR-mutated NSCLC (ENSURE)
NCT01342965Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2011
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Mar 2011; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01342965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01342965.